Tags

Type your tag names separated by a space and hit enter

Does antenatal steroids treatment prior to elective cesarean section at 34-37 weeks of gestation reduce neonatal morbidity? Evidence from a case control study.
Arch Gynecol Obstet. 2018 01; 297(1):101-107.AG

Abstract

OBJECTIVE

To determine whether antenatal corticosteroids administration prior to an elective cesarean section (ECS) at 34-37 weeks gestation is associated with improved neonatal outcome.

MATERIALS AND METHODS

A case control study of women with singleton pregnancies who underwent ECS between 34 and 37 weeks of gestation including two groups: (1) study group in which patients were treated with betamethasone prior to ECS (n = 58) and (2) control group matched for gestational age at delivery in which patients did not receive betamethasone (n = 107). Neonatal measures including respiratory distress syndrome (RDS), transient tachypnea of the newborn (TTN), oxygen requirement, admission to the special care unit, hypoglycemia, hyperbilirubinemia and length of hospitalization were determined in both groups. Composite respiratory morbidity was defined as the presence of either RDS, TTN, mechanical ventilation or oxygen requirement.

RESULTS

There was no significant difference in the rate of composite respiratory morbidity nor its components between patients with and without betamethasone treatment (25.9 vs. 25.2%, respectively, p = 0.9).

CONCLUSION

Antenatal treatment with corticosteroids prior to ECS at 34-37 weeks of gestation did not result in significant reduction in neonatal respiratory morbidity in our cohort of patients.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Sheba Medical Center, 52621, Tel-Hashomer, Israel. michal.siegel@gmail.com.Department of Obstetrics and Gynecology, Sheba Medical Center, 52621, Tel-Hashomer, Israel. Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.Department of Obstetrics and Gynecology, Sheba Medical Center, 52621, Tel-Hashomer, Israel.Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel. Department of Neonataology, Edmond and Lily Safra Children Hospital, Sheba Medical Center, Tel-Hashomer, Israel.Department of Obstetrics and Gynecology, Sheba Medical Center, 52621, Tel-Hashomer, Israel. Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.Department of Obstetrics and Gynecology, Sheba Medical Center, 52621, Tel-Hashomer, Israel. Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.Department of Obstetrics and Gynecology, Sheba Medical Center, 52621, Tel-Hashomer, Israel. Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29067513

Citation

Kirshenbaum, Michal, et al. "Does Antenatal Steroids Treatment Prior to Elective Cesarean Section at 34-37 Weeks of Gestation Reduce Neonatal Morbidity? Evidence From a Case Control Study." Archives of Gynecology and Obstetrics, vol. 297, no. 1, 2018, pp. 101-107.
Kirshenbaum M, Mazaki-Tovi S, Amikam U, et al. Does antenatal steroids treatment prior to elective cesarean section at 34-37 weeks of gestation reduce neonatal morbidity? Evidence from a case control study. Arch Gynecol Obstet. 2018;297(1):101-107.
Kirshenbaum, M., Mazaki-Tovi, S., Amikam, U., Mazkereth, R., Sivan, E., Schiff, E., & Yinon, Y. (2018). Does antenatal steroids treatment prior to elective cesarean section at 34-37 weeks of gestation reduce neonatal morbidity? Evidence from a case control study. Archives of Gynecology and Obstetrics, 297(1), 101-107. https://doi.org/10.1007/s00404-017-4557-8
Kirshenbaum M, et al. Does Antenatal Steroids Treatment Prior to Elective Cesarean Section at 34-37 Weeks of Gestation Reduce Neonatal Morbidity? Evidence From a Case Control Study. Arch Gynecol Obstet. 2018;297(1):101-107. PubMed PMID: 29067513.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Does antenatal steroids treatment prior to elective cesarean section at 34-37 weeks of gestation reduce neonatal morbidity? Evidence from a case control study. AU - Kirshenbaum,Michal, AU - Mazaki-Tovi,Shali, AU - Amikam,Uri, AU - Mazkereth,Ram, AU - Sivan,Eyal, AU - Schiff,Eyal, AU - Yinon,Yoav, Y1 - 2017/10/24/ PY - 2017/06/03/received PY - 2017/09/28/accepted PY - 2017/10/27/pubmed PY - 2019/2/12/medline PY - 2017/10/26/entrez KW - Antenatal corticosteroids KW - Elective cesarean section KW - Late prematurity KW - Neonatal morbidity SP - 101 EP - 107 JF - Archives of gynecology and obstetrics JO - Arch. Gynecol. Obstet. VL - 297 IS - 1 N2 - OBJECTIVE: To determine whether antenatal corticosteroids administration prior to an elective cesarean section (ECS) at 34-37 weeks gestation is associated with improved neonatal outcome. MATERIALS AND METHODS: A case control study of women with singleton pregnancies who underwent ECS between 34 and 37 weeks of gestation including two groups: (1) study group in which patients were treated with betamethasone prior to ECS (n = 58) and (2) control group matched for gestational age at delivery in which patients did not receive betamethasone (n = 107). Neonatal measures including respiratory distress syndrome (RDS), transient tachypnea of the newborn (TTN), oxygen requirement, admission to the special care unit, hypoglycemia, hyperbilirubinemia and length of hospitalization were determined in both groups. Composite respiratory morbidity was defined as the presence of either RDS, TTN, mechanical ventilation or oxygen requirement. RESULTS: There was no significant difference in the rate of composite respiratory morbidity nor its components between patients with and without betamethasone treatment (25.9 vs. 25.2%, respectively, p = 0.9). CONCLUSION: Antenatal treatment with corticosteroids prior to ECS at 34-37 weeks of gestation did not result in significant reduction in neonatal respiratory morbidity in our cohort of patients. SN - 1432-0711 UR - https://www.unboundmedicine.com/medline/citation/29067513/Does_antenatal_steroids_treatment_prior_to_elective_cesarean_section_at_34_37_weeks_of_gestation_reduce_neonatal_morbidity_Evidence_from_a_case_control_study_ L2 - https://dx.doi.org/10.1007/s00404-017-4557-8 DB - PRIME DP - Unbound Medicine ER -